News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio With Three New Antigens Via Series Of Rights Acquisitions


6/10/2014 10:13:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline. These three antigens are in addition to the Company’s agglutinin-like sequence 3 (Als3) antigen used in NDV-3, NovaDigm’s lead vaccine being evaluated in an on-going Phase 1b/2a study.1 NovaDigm now has four of the five most widely studied Candida antigens, and two of those have successfully completed Phase 1 studies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES